Can Adagrasib treat colorectal cancer patients?

Adagrasib is an oral small molecule inhibitor that targets the KRAS G12C mutation and was originally developed to treat patients with non-small cell lung cancer. With the deepening of research, scientists gradually discovered that KRAS G12C mutations not only appear in lung cancer, but also occur in a certain proportion in various solid tumors such as colorectal cancer. Therefore, adagrasib is currently being explored for the treatment of patients with advanced colorectal cancer (CRC) carrying KRAS G12C mutations, and has shown certain efficacy in some clinical studies.

According to clinical trial data, adagrasib has certain anti-tumor activity in patients with KRAS G12C mutated colorectal cancer. Especially when combined with EGFR inhibitors (such as cetuximab), its efficacy is more significant. Studies believe that because KRAS G12C mutations in colorectal cancer are still dependent on the EGFR signaling pathway, the combined use of EGFR inhibitors can help overcome drug resistance and improve treatment response and disease control rates.

In a clinical study called KRYSTAL-1, researchers evaluated adagrasib alone and in combination with cetuximab in patients with advanced KRAS G12C mutated colorectal cancer. The results showed that the objective response rate of monotherapy was relatively low, while the response rate after combination treatment increased significantly, and some patients' lesions were significantly reduced and the disease control time was prolonged. These results provide new treatment options for KRAS G12C mutated colorectal cancer and demonstrate the potential of adagrasib in this patient population.

In general, adagrasib is not yet officially approved for the treatment of colorectal cancer, but it has shown positive signals in clinical trials. For patients with advanced colorectal cancer diagnosed with KRAS G12C mutations, if the standard treatment regimen is ineffective and they are eligible to participate in clinical trials or obtain drugs through reasonable channels, adagrasib can be considered as a potential option. However, genetic testing must be conducted under the guidance of a professional doctor before taking the drug, and the indications, risks and feasibility of the drug must be evaluated.

References：https://www.krazati.com/